Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 4/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23464921 | 0.85 | KDM1A (0.46) | KDM1ANPSR1 | |
| SCHEMBL13589512 | 0.80 | PIK3CD (0.48) | PIK3CDCYP1A2TDP1SIGMAR1DRD3 | |
| SCHEMBL5482353 | 0.80 | PIK3CD (0.48) | PIK3CDCYP1A2TDP1SIGMAR1DRD3 | |
| SCHEMBL13451388 | 0.80 | KDM1A (0.43) | KDM1A | |
| SCHEMBL12744445 | 0.77 | CARM1 (0.46) | HRH3CYP2C19KDM1AALDH1A1 | |
| SCHEMBL23823660 | 0.77 | CYP1A2 (0.64) | PIK3CDCYP1A2TDP1SIGMAR1DRD3 | |
| SCHEMBL13588757 | 0.76 | PIK3CD (0.53) | PIK3CDCYP1A2TDP1SIGMAR1DRD3 | |
| SCHEMBL12744429 | 0.76 | CARM1 (0.45) | SIGMAR1HRH3KDM1AALDH1A1 | |
| SCHEMBL3314840 | 0.74 | CARM1 (0.54) | PIK3CDCYP1A2TDP1SIGMAR1DRD3 | |
| SCHEMBL12744430 | 0.74 | KDM1A (0.48) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910611-B2 | Therapeutic agent for restenosis | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20100029625-A1 | Therapeutic Agent for Restenosis | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029625-A1 | Therapeutic Agent for Restenosis | NR1H2, NR1H3, LDLR | PIK3CD 2263/4885CYP1A2 1325/4885TDP1 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.